Virtual Library
Start Your Search
Mingyi Di
Author of
-
+
P1.01 - Advanced NSCLC (ID 757)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.01-061 - The Efficacy and Safety of Anti-PD-1 in the Treatment of Non-Small Cell Lung Cancer (NSCLC): Systematic Review (ID 9221)
09:30 - 09:30 | Presenting Author(s): Mingyi Di
- Abstract
Background:
Non-small cell lung cancer (NSCLC) patients treated with standard chemotherapies experience progression rapidly. A novel therapy based on programed death 1 (PD-1) inhibitors showed an increasing potential in several malignancies including advanced NSCLC.This article is a meta-analysis aiming to systematically evaluate the efficacy and safety profiles of PD-1 agents in patients with NSCLC.
Method:
Data sources: Data were collected from eligible studies searched from PubMed, Embase, and Cochrane. Synthesis methods: Pooled hazard ratio (HR) for overall survival (OS) and progression-free survival (PFS) was estimated to assess the efficacy of PD-1 inhibitors versus docetaxel, pooled odds ratio (OR) was calculated for objective response rate (ORR). OR for occurrence of any grade and grade 3 to 5 treatment related adverse effect was calculated for evaluating the safety of PD-1 therapies.
Result:
Five studies were included in this analysis. The pooled HRs for OS and PFS were 0.66 (95% CI 0.60–0.74; P<0.00001) and 0.78 (95% CI 0.71–0.86; P<0.00001) respectively, the pooled OR for ORR was 2.12 (95% CI 1.50–2.98; P<0.0001), indicating a significant improvement in OS, PFS, and ORR. OR for occurrence was 0.78 (95% CI 0.63–0.96; P=0.02) in any grade treatment-related adverse effect and 0.27(95% CI 0.23–0.33; P<0.00001) in grade 3 to 5 treatment-related adverse effect, suggesting a superior safety profile of PD-1 inhibitors.
Conclusion:
The anti-PD-1 therapy can significantly prolonge the OS、PFS,improve the ORR and can also reduce the treatment-related adverse effect events versus standard chemotherapies.
-
+
P2.15 - SCLC/Neuroendocrine Tumors (ID 716)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: SCLC/Neuroendocrine Tumors
- Presentations: 1
- Moderators:
- Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.15-012 - Analysis of Small Cell Lung Cancer with Paraneoplastic Limbic Encephalitis (ID 9148)
09:30 - 09:30 | Presenting Author(s): Mingyi Di
- Abstract
Background:
Section not applicable
Method:
The clinical data of 15 patients with small cell lung cancer(SCLC) combined with paraneoplastic limbic encephalitis(PLE) from 1980 to 2017 were collected from Peking Union medical college hospital. Their symptoms and laboratory data were analyzed and the prognosis of the patients was followed.
Result:
1. PLE is a rare disease, the incidence rate in small cell lung cancer is about 0.842%.The data may be underestimated because of misdiagnose or missed diagnosis. 2. High incidence crowd of the disease is the middle-aged male smoker, The TNM stages of them are later than others. 3. Typical neurological symptoms include varying degrees of short-term memory loss, seizures and varying degrees of mental disorders; neurological symptoms usually occur before the onset of cancer or respiratory symptoms appear, an average of about 2 months be taken from onset to diagnosis. 4. Serum antibody (anti-Hu, GABA-R-Ab), cerebrospinal fluid, head MRI and EEG of the patients has abnormalities; Videography, especially CT is a good means of screening the primary tumor, pathology diagnosis mainly rely on bronchoscopy. 5. The treatment of primary tumors can be more effective in alleviating the nervous system symptoms than immunotherapy.
Conclusion:
Paraneoplastic limbic encephalitis is a rare paraneoplastic syndrome in nervous system caused by malignant neoplasms often characterized by facial neurological symptoms. The disease are usually associated with lung cancer (especially small cell lung cancer) .Its nervous system symptoms occur earlier than the tumor diagnosis. Early diagnosis and treatment for primary tumors will increase the benefit.
